Skip to main content
Midas Edge

BiomX Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

Redeemable Convertible Preferred Shares · Common stock · Additional paid in · Accumulated · Total Stockholder’
SharesAmountSharesAmountcapitaldeficitequity
Balance as of January 1, 2025147,73518,64518,176,6616186,194(180,697)24,148
Issuance of Common Stock, Registered Pre-Funded Warrants and Private Pre-Funded Warrants under the February 2025 SPA, net of issuance costs (**)2,828,283*878878
Issuance of Common Stock under Inducement Letter Agreements (**)3,961,10916,4726,473
Stock-based compensation expenses659659
Net loss---(7,659)(7,659)
Balance as of March 31, 2025147,73518,64524,966,0537194,203(188,356)24,499
Exercise of Private Pre-Funded Warrants and Common Warrants (**)1,202,314*2-2
Issuance of Common Stock upon restricted stock units vesting (***)274,890*--*
Stock-based compensation expenses696696
Net loss(6,037)(6,037)
Balance as of June 30, 2025147,73518,64526,443,2577194,901(194,393)19,160
Exercise of Private Pre-Funded Warrants (**)226,930**
Issuance of Common Stock under At the Market Sales Agreement, net of $3 issuance costs (**)108,493*5454
Stock-based compensation expenses438438
Conversion of Redeemable Convertible Preferred Shares into Common Stock (**)(223)(28)22,300*28-
Net loss(9,166)(9,166)
Balance as of September 30, 2025147,51218,61726,800,9807195,421(203,559)10,486
(*)Less than $1.
(**)See Note 9A.
(***)See Note 9B.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

Redeemable Convertible Preferred Shares · Redeemable Convertible Preferred Shares · Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ Equity (Capital
SharesAmountSharesAmountSharesAmountCapitalDeficitDeficiency)
Balance as of January 1, 2024----4,723,3803166,048(162,970)3,081
Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost (**)40,47012,561--916,49713,227-3,228
Exercise of Pre-Funded Warrants into shares of Common Stock (**)--477,827*5-5
Issuance of Common Stock under At the Market Sales Agreement, net of $1 issuance costs (**)--7,518*19-19
Stock-based compensation expenses----909-909
Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs (**)216,41719,859----541541
Net loss----(17,327)(17,327)
Balance as of March 31, 2024256,88732,420--6,125,2224170,749(180,297)(9,544)
Exercise of Pre-Funded Warrants into shares of Common Stock (**)--980,8111--1
Stock-based compensation expenses---77-77
Reclassification of Redeemable convertible preferred Shares to equity(256,887)(32,420)256,88732,420----32,420
Net income--4,4714,471
Balance as of June 30, 2024--256,88732,4207,106,0335170,826(175,826)27,425
Redeemable Convertible Preferred Shares conversion into shares of Common Stock (**)(109,152)(13,775)10,915,200113,774-
Issuance of Common Stock upon restricted stock units (“RSU”) vesting--155,429*--*
Stock-based compensation expenses----829-829
Net income-----9,6429,642
Balance as of September 30, 2024--147,73518,64518,176,6626185,429(166,184)37,896
(*)Less than $1.
(**)See Note 9A.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.